東陽光藥：中期報告2019.pdf

《東陽光藥：中期報告2019.pdf》由会员分享，可在线阅读，更多相关《東陽光藥：中期報告2019.pdf（82页珍藏版）》请在三个皮匠报告上搜索。

1、YiChang HEC Changjiang Pharmaceutical Co.,Ltd.宜昌東陽光長江藥業股份有限公司Interim Report 2019 中期報告Interim Report2 0 1 9中期報告OUR MISSIONHEALTH我們的使命為每個人的健康Interim Re eporept中期報報報報報報報告告告告告告告FOR EVERYONESCONTENTS目錄Financial Highlights財務摘要2Corporate Profile公司簡介3Management Discussion and Analysis管理層討論及分析4Corporate Gove

2、rnance and Other Information企業管治及其他資料27Review Report審閱報告41Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表43Consolidated Statement of Financial Position綜合財務狀況表44Consolidated Statement of Changes in Equity綜合權益變動表46Consolidated Cash Flow Statement綜合現金流量表48Notes to th

3、e Unaudited Interim Financial Information未經審核中期財務資料附註49Corporate Information公司資料78YICHANG HEC CHANGJIANG PHARMACEUTICAL CO.,LTD.宜昌東陽光長江藥業股份有限公司 2FINANCIAL HIGHLIGHTS財務摘要Six monthsended30 June2019截至二零一九年六月三十日止六個月Six monthsended30 June2018截至二零一八年六月三十日止六個月Year ended 31 December截至十二月三十一日止年度(RMB000)（人民幣千

4、元）201820172016 Revenue營業額3,071,2591,482,4282,510,4761,601,567941,504Gross profit毛利2,620,8201,243,4332,111,6671,321,151727,270Profit from operations經營溢利1,257,067747,3831,103,742752,484460,299Profit before taxation除稅前溢利1,172,634746,8631,102,324748,195453,066Profit attributable to equity shareholders o

5、f the Company本公司權益股東應佔溢利968,424634,544942,536647,101380,597Basic/diluted earnings per share(RMB cent)每股基本攤薄盈利（人民幣分）21514020914384Total assets總資產9,131,2514,572,3214,560,9403,775,9752,831,109Total liabilities總負債4,865,6881,012,594882,012715,389373,302Net assets淨資產4,265,5633,559,7273,678,9283,060,5862,4

6、57,807Profitability 盈利能力Gross profit margin毛利率85.3%83.9%84.11%82.5%77.2%Operating profit margin經營溢利率40.9%50.4%50.4%47.0%48.9%Net profit margin淨利潤率31.3%41.2%35.90%39.1%40.4%INTERIM REPORT 2019 中期報告 3CORPORATE PROFILE公司簡介宜昌東陽光長江藥業股份有限公司（以下簡稱 本公司 或 東陽光藥，連同其附屬公司統稱 本集團）是一家專注於抗病毒、內分泌與代謝以及心血管等疾病治療領域進行醫藥產品研